motorway-tunnel
1 April 2013AmericasDaniel Sánchez and Victor Ramirez

Moving forward: biologics and biocomparables in Mexico

Biological drugs and the legislation and regulation surrounding them are topics that have provided more than one headache to governments around the world. If the fight between innovators and generic companies over non-biological medicines has always been more a matter of industrial property, when a biological medicine is involved, regulatory concerns increase the complexity of the debate.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
4 June 2026   Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.
Americas
3 June 2026   A district court has thrown out one challenge over the vaccine delivery technology, while a separate appeal could affect protections available to government contractors during national emergencies.
Americas
1 June 2026   A district jury has handed a J&J unit a clean sweep in its defence against a rival's heart pump patent claims, delivering a win under the seldom-invoked reverse doctrine of equivalents.